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The Appropriate Use
of Risk Scores*
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Risk prediction for cardiovascular events has gained popu-
larity in patients undergoing percutaneous coronary inter-
vention (PCI). Methods of estimating the risk of various
cardiovascular disease outcomes at different time periods
following a variety of interventions using risk score sheets
are available now on the Internet. Yet, the desire to predict
the future using these scores has begun to impact clinical
practice in selection of patients and treatment modalities.
When choosing the appropriate risk prediction model, one
should take into account the population of interest, risk
factors, treatment, procedure to be performed, and the time
frame in relation to the cardiovascular outcome. Histori-
cally, cardiovascular risk scoring systems were designed to
estimate the probability that a person would develop car-
diovascular disease within the next 5 or 10 years (1). Because
these systems provide an indication of those most likely to
develop cardiovascular disease, they also indicate those most
likely to benefit from prevention or treatment. In the past,
such cardiovascular risk scores acted as tools to help deter-
mine who should be offered preventive drugs to lower blood
pressure or cholesterol levels.
See page 1097
Since the introduction of the Framingham risk score (1),
however, we have experienced an influx of risk scores, many
of which (TIMI [Thrombolysis In Myocardial Infarction],
SYNTAX [SYNergy between PCI with TAXUS and Car-
diac Surgery], EuroSCORE [European System for Cardiac
Operative Risk Evaluation], and STS [Society of Thoracic
Surgeons]) (2–5) are dedicated to direct patient manage-
ment, and more recently, to the selection of patients
undergoing transcatheter aortic valve replacement. At-
tempts have been made to further refine these risk scores in
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In 2012, the interventional cardiologist continues to face
the practical dilemma of whether or not to implant a
drug-eluting stent (DES) or bare-metal stent for the treat-
ment of coronary lesions in symptomatic patients presenting
with acute coronary syndrome (ACS). Although the intro-
duction of DES into clinical practice has led to dramatic
decreases in restenosis and associated target vessel revascu-
larization rates, the incidence of stent thrombosis (ST),
although low, still poses a major hazard, particularly due to
the associated high mortality (6).
In this issue of JACC Cardiovascular Interventions, Dan-
gas et al. (7) take this approach a step further by developing
a risk score to predict risk for ST based on clinical
parameters among ACS patients. The authors should be
congratulated on their efforts to simplify the decision-
making process. To this, the authors used 2 large patient
databases from the HORIZONS-AMI (Harmonizing
Outcomes with RevasculariZatiON and Stents in Acute
Myocardial Infarction) and ACUITY (Acute Catheteriza-
tion and Urgent Intervention Triage strategY) trials (8,9),
then divided them into a risk score development cohort and
a validation cohort. The authors identified several clinical
parameters that allow for stratifying patient risk for ST: type
of ACS, smoking status, diabetes mellitus, prior PCI,
laboratory values, timing of intervention, lesion character-
istics, TIMI flow, and number of vessels treated.
But is there a need for yet another scoring system to
predict what is already known? As practicing physicians are
increasingly confronted with prediction tools for a variety of
clinical conditions, each case should be evaluated individu-
ally, according to the appropriate clinical scenario, and
employed in appropriate patients in whom it has been
validated.
Along these lines, in-depth evaluation of the proposed
ST prediction tool indicates that most of the parameters
included in the Dangas et al. (7) ST risk score were known
from previous ST studies (10,11). Conversely, other param-
eters, such as early discontinuation of antiplatelet therapy
and technical issues related to stent deployment (10), both
of which are considered powerful predictors for ST, were
neither evaluated nor included in the proposed risk score.
Although the model is able to categorize patients as low
(1.36%), intermediate (3.06%), and high risk (9.18%) for
ST, disregarding the potential likelihood of a patient to
comply with a long-term dual antiplatelet therapy regimen
after DES implantation would place the patient at prohib-
itive risk for ST. Accordingly, a low-risk patient who needs
a spinal surgery should not receive a DES despite his
low-risk score for ST. This model does not account for
these common scenarios; therefore, it may be misleading to
cardiologists or may lead to inappropriate use of this score.
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1107The proposed model is based on pooled ST risk data from
HORIZONS-AMI (high-risk, ST-segment elevation myo-
cardial infarction [STEMI]) and ACUITY (low- to
intermediate-risk, ACS patients); and each study also re-
ported different ST rates at 1 year (8,9). Regarding this risk
difference, the poolability of patients from these 2 studies
for the purpose of this analysis is in question. Additionally,
although the pathophysiological process and outcomes of
ST at 30 days, 30 days to 1 year, and outward are
fundamentally different, the proposed risk score is inclusive
up to 1 year from stent implantation. Therefore, it is
possible that there are different risk factors and different
levels of risk for each of these 2 study populations, as well as
for the subacute, late, and very late occurrences of ST.
Because the pathophysiological development of neointimal
formation is time dependent, the validity of a risk score that
is formulated on acute, subacute, and late ST patients is
grossly confounded (12,13). Likewise, physicians should be
cautioned against a creep in the utilization of this model for
other patient populations, such as stable PCI patients, as
this model was not tested nor validated for this large patient
population.
In addition, the proposed risk score was mainly based on
first-generation DES, and for the STEMI population in the
HORIZONS-AMI study, it was limited to only the
TAXUS stent, which was previously reported to be associ-
ated with high ST rates when compared with second-
generation DES. Accumulating data from both large ran-
domized trials and real-world registries indicate the safety of
second-generation (vs. first-generation) DES (14). Differ-
ences in stent properties, such as polymer, drug release, and
vessel healing, may impact the rates and mechanisms of ST.
Thus, it is yet to be seen whether the proposed ST risk score
is still relevant in the era of second-generation DES.
Further, the proposed risk score model does not differentiate
between the different mechanisms for early ST, which is
typically more mechanical, and very late ST, which is related
to neoatherosclerosis (15).
Prediction models are a useful tool in the physician’s
arsenal to facilitate appropriate decision-making processes
and to weigh the benefits and risks of any intervention.
Identifying correlates and predictors for cardiac events is
critical to improve outcome; therefore, lumping all of the
parameters into a risk score model is sometimes too sim-
plistic and risky. It is imperative that the user of such a
prediction tool be aware of its capabilities and performance,
as well as its limitations, in various clinical scenarios. A newly
developed risk score for ST should be robust and should be
tested across broad study populations, stents, and antiplatelet
regimens. A new model should also be validated in a setting
different from the one in which it was derived. Unfortu-
nately, this is not the case with the newly proposed model.Nevertheless, the model is an important attempt to develop
an interesting and important tool to reduce ST rates. Until
such an encompassing tool is developed and validated, one
should rely on the known ST risk factors and tailor an
appropriate treatment for each patient.
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